The new antiemetic ondansetron is effective for the prophylaxis and treatment of postoperative nausea and vomiting (PONV), but has been subject to limited comparative evaluation in surgical inpatients. Two hundred and seventy women having abdominal gynaecological surgery were investigated for 24 hours postoperatively in a randomized, double-blind, placebocontrolled study of intraoperative intravenous ondansetron 8 mg (n = 83), droperidol2.5 mg (n = 89) or saline placebo (n = 87).
Ondansetron is a selective 5-hydroxytryptamine3 (5-HT3) antagonist used in the management of postoperative nausea and vomiting (PONV), having previously been established as the prophylactic antiemetic of choice for chemotherapy and radiationinduced emesis ' . Placebo-controlled studies have shown it to be an effective anti emetic for PONY, particularly in day surgical populations 2 • Few comparative studies have been published 3-5, only one involving inpatients undergoing major surgery5. Results from outpatient populations having minor surgery may not be applicable to inpatients having major surgery, postoperative opioid analgesia and with a greater risk of PONY. Droperidol is popular prophylactically because it is more effective than many other antiemetics 6 -1O • Although it is significantly cheaper than ondansetron, in comparison with ondansetron's excellent side-effect profile'· ll , droperidol may cause drowsiness, impairment of psychomotor skills and occasionally extrapyramidal side-effects, particularly with larger therapeutic doses' 2 • The comparative efficacy of ondansetron versus droperidol is unclear, with studies reporting both greater 3 and less efficacy'3 or no significant difference '4 . ' 5 . Before the widespread acceptance of ondansetron into anaesthetic practice, its therapeutic value and cost-effectiveness needs to be well-defined by detailed comparison with other readily available anti emetics in various surgical populations 2 . '6 • It was the aim of this randomized, double-blind, placebo-controlled study to compare the efficacy and side-effects of intravenous ondansetron 8 mg and droperidol 2.5 mg as prophylactic anti emetics prior to open abdominal gynaecological surgery.
MATERIALS AND METHODS
1\vo hundred and seventy women scheduled for major open abdominal gynaecological or gynaecological oncology surgery, who gave written, informed consent, were recruited to this study, which had institutional Research and Ethics Committee approval. Women scheduled for bowel resection, those with preoperative nausea or vomiting, or on medication with anti emetic activity, were not eligible. All oncological cases involving possible ovarian malignancy received neomycin and metronidazole and a "bowel preparation" with a hypertonic solution. Patients with uterine or cervical malignancy received tinadazole only. None had preoperative radiotherapy or chemotherapy drugs. Those who underwent unplanned bowel, vaginal or laparoscopic surgery were excluded from analysis. Sample size was calculated based on a desire to detect with a type I error rate of 0.05 and a power of 0.8, a reduction in the incidence of vomiting in the first 24 hours postoperatively from 750/0 with no prophylactic antiemetic to 500/0 with either study drug, or an incidence of 30% with one study drug.
Anaesthetic technique was standardized, consisting of premedication (oral temazepam 20 mg), preoperative low thoracic (T9-T12) epidural anaesthesia to T4 (using 0.5% bupivacaine and fentanyl 100 p,g) and balanced general anaesthesia with thiopentone, nitrous oxide and volatile anaesthetic plus intravenous (IV) fentanyl as required (maximum 200 p,g). An epidural infusion of 0.1 % bupivacaine and fentanyl 10 p,g/ml at 2-8 ml/h was used for postoperative analgesia for at least 24 hours. Women were randomized to one of three groups according to a computer-derived random number sequence. The study drug, known only to the attending anaesthetist who took no further part in the study, was administered IV immediately post-induction in a 4 ml volume. Group 0 received ondansetron 8 mg, Group D droperidol2.5 mg and group P placebo (0.9% sodium chloride). Postoperatively, prochlorperazine 12.5 mg intramuscularly six hourly was used for rescue antiemetic treatment at the discretion of the attending nurse. All participants were advised that this was the only treatment drug available during the study, although they were free to withdraw from the study at any time.
Patient characteristics of age, weight, type and duration of surgery were noted. Assessments of PONV were made for three time periods, namely arousal to discharge from the recovery room; from then until 6 hours, and from 6 to 24 hours postoperatively. Nursing staff recorded the time of vomiting or retching episodes. At discharge from the recovery room, patients were asked to rate PONV experienced to that time using a verbal rating score between 0 and 10, where 0 represented "not feeling sick at all" and 10 "feeling as sick as I could possibly feel". Thereafter, a 0-100 mm visual analogue scale with extremes worded as above was used to evaluate the worst feeling of sickness experienced in the previous time period. Similar scales were used at 6 and 24 hours for the degree of drowsiness (scale extremes "completely wide awake and alert" and "as drowsy as I could possibly feel"). The number of episodes of vomiting/retching (vomits or retches one minute apart were considered separate episodes) and the number of doses of rescue anti emetic given were noted. At 24 hours, patients were asked if they had experienced headache; blurring of or difficulty with vision; muscle twitches or unusual movements; an unexpected feeling of agitation or restlessness; or to comment on any other symptoms.
Age and weight were analysed with the F-test. Howver, as most variables were not normally distributed, most data were described using median and interquartile range and non-parametric methods of analysis were used. At each assessment time, all three groups were compared using Kruskall-Wallis chi-squared test for numeric values and chi-squared test for categorical values. Wilcoxon's rank-sum test or Fisher's exact test were used to compare groups 0 and D. Differences for the time to first vomiting were treated as survival data and tested by the log likelihood test. Logistic regression analyses, adjusted for various variables, were performed for the presence of vomiting or nausea during each period. A P value of < 0.05 was considered statistically significant.
RESULTS
Two hundred and seventy women were enrolled and eleven excluded from analysis, due to vaginal or bowel surgery (6), protocol violation (2), inadequate data collection (2) and premature dislodgement of an extradural catheter (1) . Included in the analysis of 259 sets (group 0, n=83; group D, n=89; group P, n=87) were 15 women who requested withdrawal due to intractable PONV not responding to rescue antiemetic. One came from group 0 versus six and eight from groups D and P respectively (P=0.06).
Patient group characteristics did not differ significantly between the three groups ( Table 1 ). Almost 90% of the gynaecological procedures were abdominal hysterectomy, the remainder being ovarian cystectomy and/or salpingectomy. Gynaecological oncology patients all had a vertical midline lower abdominal incision and underwent, according to preoperative diagnosis and staging, radical or modified radical hysterectomy, with para-aortic lymph node biopsy with or without pelvic node dissection; or removal of pelvic mass with node biopsy with or without debulking of ovarian malignancy with omentectomy. Vomiting at some time during the first postoperative day was more likely in those with a past history of PONV (n=74, odds ratio 1.9, Cl 1-3.8). This increased likelihood was maximal during the period spent in the recovery room (odds ratio 3.2, Cl 1.7-6.1). Vomiting was less likely in gynaecological oncology patients (odds ratio 0.6, Cl 0.3-1.1). Ondansetron and droperidol were both equally likely to prevent vomiting in the recovery room (odds ratio versus placebo 0.4, Cl 0.2-0.9), but ondansetron more likely over the entire study period (odds ratio 0.5, Cl 0.3-1) ( Figure 1 The incidence of vomiting in the recovery room was 30070,25% and 44% (P<0.05, group 0 versus D versus P) and in the first 24 hours postoperatively 72%,83% and 91%. Groups 0 and D had significantly fewer 10 patients who vomited than group P, both in each individual period and over the entire 24 hours ( Figure  2 ). The incidence of vomiting in all patients and in the subset with a previous history of PONV ( Figure 3 ) did not differ between groups 0 and D during any time period, including the entire 24 hour period. The time to first vomit ( Figure 4 ) was significantly longer in groups 0 and D versus P (p<O.OOOl), although the difference between groups 0 and D was not significant (P=0.08). The number of vomiting episodes was significantly lower at all times for groups 0 and D versus P, and for group 0 versus D between leaving the recovery room and six hours postoperatively and over the entire 24 hour study period ( Figure 5 ). In patients with a past history of PONV, the number of vomits was significantly less in groups 0 and D (versus .., ., Nausea, in terms of the number of patients with a zero score, was significantly less in groups 0 and D in the recovery room and between 6 and 24 hours, and median nausea score was also significantly lower after leaving the recovery room. Nausea was also less common after six hours in group 0 versus D ( Table  2 ). In patients with a history of PONY, however, there was no significant difference between groups for the incidence or severity of nausea. The need for antiemetic rescue treatment was significantly lower at all times in Anaesthesia and Intensive Care, Vol. 23, No. 5, October 1995 groups 0 and D versus P ( Figure 6 ), although in the subset of patients with a past history of PONY, a reduction was evident only in the recovery room (P=0.02). TABLE 2 Incidence and severity of nausea Values are median and interquartile range for nausea score. P values for the percentage with no nausea are derived from the chi-squared test ( . Sedation scores were significantly higher in group D at six hours (median 70, interquartile range 40-80 versus 50, 25-70 group 0 and 60, 40-80 group P, P=O.Ol), but there was no significant difference between groups thereafter. Group D had a significantly lower incidence of postoperative headache and group P a significantly higher incidence of unexpected muscle movement, but the incidence of visual disturbance and agitation did not differ between groups (Thble 3). There were no other potentially adverse effects noted in any group. 
Patient group characteristics Values are mean and standard deviation for age and weight and median and interquartile range for duration of surgery. P values are derivedfrom the F-test and the Kruskall-Wallis chi-squared test respectively and from the chi-squared test for the type of operation and history of PONV
Wilcoxon rank sum test (0 v D). Group 0 Group D Group P p(0 v D PtO v D) v P)
DISCUSSION
Major gynaecological surgery is associated with possibly the highest incidence of PONY, between 60 and 83070 of patients experiencing emetic sequelae 17 . 19 . The incidence in our placebo group was over 90070 and, despite prophylaxis, three-quarters of those receiving prophylactic therapy vomited during the first 24 postoperative hours. This gives some support to comparative studies and reviews 20 . 21 which highlight the failure of prophylaxis to reduce the impact of PONY significantly.
Study groups were similar for gender, age, type of surgery, anaesthetic and postoperative pain management, and history of previous PONY. These are important independent factors for postoperative sickness and balancing patient groupS20.22. The clinical impact of single-dose prophylaxis with ondansetron was relatively modest, because it was only more effective than droperidol with respect to diminishing the severity of PONY. It did not significantly reduce the incidence of vomiting or the need for rescue antiemetic treatment. This is nevertheless of some importance, since many anaesthetists and investigators have previously considered droperidol the most effective available prophylactic antiemetic for PONY.
Droperidol is a better anti emetic for PONY than metoclopramide, domperidone and scopolamine 61O . In this study, intravenous droperidol 2.5 mg administered at induction prevented PONY in only 27% of patients. A third vomited in the first six hours postoperatively. Madej et al 7 reported similar results, with vomiting in 60% of the placebo group and over 30% of the droperidol group during the first six hours. In contrast, another study in gynaecological inpatients found droperidol 2.5 mg prevented vomiting for 24 hours in 67% of cases 9 . Possible explanations include population differences and our exclusion of major vaginal surgical procedures, which may be associated with a lower risk 22 . In addition we included oncology patients, who unexpectedly proved to have a lower risk of vomiting than other gynaecological patients.
Intravenous droperidol has an elimination half-life of about two hours and the suggestion that administration at the end of surgery might improve results 20 warrants evaluation, since we found that droperidol reduced the severity of nausea and vomiting in the recovery room as effectively as ondansetron, but not subsequently. A dose of 2.5 mg is as effective as 5 mg in this setting 9 but smaller doses have not been investigated beyond this phase. Madej et aF found no increase in sedation or abnormal movements after droperidol 2.5 mg, but we, like Mortensen 9 , noted greater drowsiness in the early postoperative period after droperidol. Even very small therapeutic doses may impair psychomotor recovery and cause restlessness and anxiety23. Extrapyramidal effects are uncommon but may occur with as little as 0.65 mg and be delayed in presentation 24 • Like others 6 -1o . we did not notice extrapyramidal effects or agitation, although detailed assessment was not performed. Droperidol resulted in a significantly lower incidence of headache than placebo or ondansetron, the explanation for this observation being unclear.
Ondansetron, the first of the 5-hydroxytryptamine3 (56-HT3) receptor antagonists, probably acts in both the intestinal mucosal and central chemoreceptor trigger zone. Several aspects relevant to the optimum prophylactic use of ondansetron remain unclear. The elimination half-life is 3.5 to 4 hours\ so administration near the end of surgery may be preferable, but the timing of prophylaxis has yet to be investigated 16 . Although 4 mg IV is the recommended prophylactic dose, this is based on placebo-controlled studies after minor surgery, and we chose 8 mg based on available information at the time of commencing this study, when the drug had yet to be approved for PONY. After major surgery, 8 mg IV or orally is significantly more effective than placebo17-19.22.25 and the only IV doseresponse study concluded that 8 mg was as effective as 16 mg and significantly better than 1 mg, but did not investigate other doses 17 • The optimum oral dose is 8 mg22.25 and as oral bioavailability is 60%\ further dose-response studies are needed to determine whether 4 mg IV is as effective as 8 mg for prophylaxis prior to major surgery. The influence of opioid analgesia on dose requirement is also undetermined. Tropisetron, a drug of similar class, was ineffective in reducing subarachnoid morphine-induced emesis 26 . Ondansetron 8 mg IV is more effective than 4 mg in outpatients receiving general anaesthesia with alfentanip7 and produces a 30% difference in complete response (no emetic episodes) compared with placebo after opioid is administered to volunteers 28 • We found about a 20% difference in complete response in postoperative patients receiving opioid analgesia and approximately Anaesthesia and Intensive Care. Vo/. 23, No. 5, October 1995 double the percentage of women having no nausea compared with both placebo and droperidol.
Our single-dose study found antiemetic efficacy similar to that of multiple-dose studies in gynaecological inpatients I8 ,19,22 although our results support the possible benefit of a repeat dose of ondansetron at about six hours postoperatively, since thereafter a benefit compared with droperidol was less evident, only being significant with respect to the severity of nausea. Ondansetron is well-tolerated; has no cardiovascular effects when given rapidly intravenously; does not impair recovery; or alter mood, sedation and ventilatory responses after alfentaniF9,30. Side-effects (e.g. headache and constipation) are mild and we, like others I7 ,18, found a side-effect profile similar to placebo.
Some comparative studies of prophylactic ondansetron for ambulatory surgery suggest it is a more effective antiemetic than metoclopramide, ephedrine or droperidop,4, while others disagree 13 • ls ,31,32. Some advantage is reported in orthopaedic inpatients S ,33 but the only other comparative study to use extradural opioids postoperativelyS found ondansetron to be no more effective than droperidol in reducing the incidence of vomiting and nausea, although the severity of nausea and the need for antiemetic treatment were reduced. Our results also supported reduced severity, but not incidence, of vomiting, and reduced nausea. Methodological differences in the study by Gan and colleagues S included their use of lower drug doses (4 mg and 1.25 mg respectively) and an orthopaedic population with a lower risk of PONY.
It is assumed that those who would benefit most from prophylactic therapy are patients with a history of previous PONY, and in this study this group was twice as likely to vomit after leaving the recovery room. Ondansetron was not superior to droperidol however, with the exception of reducing the number of vomiting episodes in the early postoperative period. This is similar to the results obtained in a small outpatient study of those with a history of PONV32.
The side-effect profIles of the two drugs differed with respect to the degree of early sedation and the incidence of headache, though neither appeared of major clinical importance in this setting.
The financial and clinical impact of the differences detected in this study was not addressed. Pharmacoanalysis has established the cost-effectiveness of ondansetron compared to other regimens for highly emetogenic chemotherapy34. The financial cost of emesis after major gynaecological surgery has been estimated, based on the cost of antiemetic therapy and extra medical time treating patients in United Kingdom hospitals 3s . The acquisition cost of ondansetron, as used in this study, was about nine times that of droperidol. Total cost analysis of PONY must consider both direct (nursing and medical time, drugs and supplies) and indirect costs (time lost and increased postoperative morbidity and length of stay)36. Since it is possible that reductions in PONY may increase hospital efficiency and reduce total cost, detailed analysis of cost-effectiveness in this setting would be of interest. The human impact of PONY has also received little attention. However, in one study9, 71070 of those dissatisfied with their postoperative condition were so because PONY, and patients may be willing to "trade off" a variety of factors, including pain and increased cost, to avoid PONV37. Although the addition of metoclopramide to ondansetron did not enhance its efficacy in patients having outpatient lithotripsy38, the limited efficacy of single-drug therapy suggests combination antiemetic prophylaxis should be further investigated in high-risk populations.
CONCLUSION
This study has shown neither droperidol nor ondansetron have a major impact, as single-dose prophylactic antiemetics, on PONY after major abdominal gynaecological surgery. They are equally effective in reducing the overall incidence of vomiting; early postoperative nausea, and need for rescue antiemetic therapy, although the majority of patients in all groups vomited and received treatment for PONY at some time during the first 24 hours after surgery. Ondansetron was more effective than droperidol in reducing the severity of vomiting, and the incidence of late nausea. Further investigation of ondansetron, alone and in combination with other anti emetics, is required to determine its optimum intravenous dose, timing of administration and dosing regimen in this setting.
